TERT Expression and Clinical Outcome in Pulmonary Carcinoids
Journal of Clinical Oncology · 10.01.2025 · 43 (2) · 214-225
DOI: 10.1200/jco.23.02708 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Clinical Oncology, erschienen am 10.01.2025. Verfasst von Lisa Werr und 35 weiteren Autor:innen. Beteiligte Einrichtung: Department of Experimental Pediatric Oncology, University Children's Hospital of Cologne, Cologne, Germany. Hauptthemen laut MEDLINE: Telomerase, Carcinoid Tumor, Lung Neoplasms. Die Arbeit wurde bisher 20-mal zitiert (Crossref) und nennt 50 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: World Health Organization, NCI NIH HHS.
Abstract (Originalsprache)
PURPOSE The clinical course of pulmonary carcinoids ranges from indolent to fatal disease, suggesting that specific molecular alterations drive progression toward the fully malignant state. A similar spectrum of clinical phenotypes occurs in pediatric neuroblastoma, in which activation of telomerase reverse transcriptase ( TERT ) is decisive in determining the course of disease. We therefore investigated whether TERT expression defines the clinical fate of patients with pulmonary carcinoid. METHODS TERT expression was examined by RNA sequencing in a test cohort and a validation cohort of pulmonary carcinoids (n = 88 and n = 105, respectively). A natural TERT expression cutoff was determined in the test cohort on the basis of the distribution of TERT expression, and its prognostic value was assessed by Kaplan-Meier survival estimates and multivariable analyses. Telomerase activity was validated by telomere repeat amplification protocol assay. RESULTS Similar to neuroblastoma, TERT expression exhibited a bimodal distribution in pulmonary carcinoids, separating tumors into TERT -high and TERT- low subgroups. A natural TERT cutoff discriminated unfavorable from favorable clinical courses with high accuracy both in the test cohort (5-year overall survival [OS], 0.547 ± 0.132 v 1.0; P < .001) and the validation cohort (5-year OS, 0.788 ± 0.063 v 0.913 ± 0.048; P < .001). In line with these findings, telomerase activity was largely absent in TERT -low tumors, whereas it was readily detectable in TERT- high carcinoids. In multivariable analysis considering TERT expression, histology (typical v atypical carcinoid), and stage (≤IIA v ≥IIB), high TERT expression was an independent prognostic marker for poor survival, with a hazard ratio of 5.243 (95% CI, 1.943 to 14.148; P = .001). CONCLUSION Our data demonstrate that high TERT expression defines clinically aggressive pulmonary carcinoids with fatal outcome, similar to neuroblastoma, indicating that activation of TERT may be a defining feature of lethal cancers.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Experimental Pediatric Oncology, University Children's Hospital of Cologne, Cologne, Germany.
- Center for Molecular Medicine Cologne (CMMC), Medical Faculty, University of Cologne, Cologne, Germany.
- Else Kröner Forschungskolleg Clonal Evolution in Cancer, University Hospital Cologne, Cologne, Germany.
- Department of Translational Genomics, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany.
- Rare Cancers Genomics Team (RCG), Genomic Epidemiology Branch (GEM), International Agency for Research on Cancer/World Health Organisation (IARC/WHO), Lyon, France.
- Institute of Medical Statistics and Computational Biology, Medical Faculty, University of Cologne, Cologne, Germany.
ORCID-Profile: Lisa Werr, Christoph Bartenhagen, Carolina Rosswog, Catherine Voegele, Alex Di Genova, Angela Ernst, Yvonne Kahlert, Stefanie Höppner, Audrey Mansuet Lupo, Giuseppe Pelosi, Luka Brcic, Graziella Bosco, Mee Sook Roh, Rachel E Fanaroff, Christina J Falcon, Reinhard Büttner, Natasha Rekhtman, Charles M Rudin, William D Travis, Nicolas Alcala, Lynnette Fernandez-Cuesta, Matthieu Foll, Martin Peifer, Matthias Fischer
Förderung
- World Health Organization
- NCI NIH HHS
Zitieren
APA
Werr, L., Bartenhagen, C., Rosswog, C., Cartolano, M., Voegele, C., Sexton-Oates, A., Di Genova, A., Ernst, A., Kahlert, Y., Hemstedt, N., Höppner, S., Mansuet Lupo, A., Pelosi, G., Brcic, L., Papotti, M., George, J., Bosco, G., Quaas, A., Tang, L. H., …, & Lung NEN Network (2025). TERT Expression and Clinical Outcome in Pulmonary Carcinoids. Journal of Clinical Oncology, 43(2), 214-225. https://doi.org/10.1200/jco.23.02708
Vancouver
Werr L, Bartenhagen C, Rosswog C, Cartolano M, Voegele C, Sexton-Oates A, et al. TERT Expression and Clinical Outcome in Pulmonary Carcinoids. Journal of Clinical Oncology. 2025;43(2):214-225. doi:10.1200/jco.23.02708
BibTeX
@article{Werr2025,
author = {Werr, Lisa and Bartenhagen, Christoph and Rosswog, Carolina and Cartolano, Maria and Voegele, Catherine and Sexton-Oates, Alexandra and Di Genova, Alex and Ernst, Angela and Kahlert, Yvonne and Hemstedt, Nadine and Höppner, Stefanie and Mansuet Lupo, Audrey and Pelosi, Giuseppe and Brcic, Luka and Papotti, Mauro and George, Julie and Bosco, Graziella and Quaas, Alexander and Tang, Laura H and Robzyk, Kenneth and Kadota, Kyuichi and Roh, Mee Sook and Fanaroff, Rachel E and Falcon, Christina J and Büttner, Reinhard and Lantuejoul, Sylvie and Rekhtman, Natasha and Rudin, Charles M and Travis, William D and Alcala, Nicolas and Fernandez-Cuesta, Lynnette and Foll, Matthieu and Peifer, Martin and Thomas, Roman K and Fischer, Matthias and Lung NEN Network, Lung NEN Network},
title = {TERT Expression and Clinical Outcome in Pulmonary Carcinoids},
journal = {Journal of Clinical Oncology},
year = {2025},
volume = {43},
number = {2},
pages = {214--225},
doi = {10.1200/jco.23.02708}
}
EUVIMED